Colorectal Neoplasms
Conditions
Brief summary
The objective is to investigate the efficacy and safety of envafolimab combined with recombinant human endostatin (endostatin) in the treatment of MSS-type colorectal cancer patients with recurrence or metastasis after failure of second-line standard therapy.
Detailed description
This study is a multicenter, prospective, single-arm clinical study. That is, eligible colorectal cancer patients, after signing the informed consent form, are screened into the group, and will receive continuous intravenous infusion of envafolimab (envafolimab) combined with recombinant human endostatin (endostatin) until the disease. Progressive or intolerable.
Interventions
DRUGEnvafolimab
300mg,sc,d3,Q3W;
DRUGrecombinant human endostatin (endostatin)
210mg,civ,d1-3,Q3W
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The subjects voluntarily joined the study, signed the informed consent form, and had good compliance; * 18-75 years； * ECOG 0-1； * life expectancy of at least 3 months； * Pathological specimens can be provided for biomarker detection * Patients with recurrent or metastatic advanced MSS-type colorectal adenocarcinoma diagnosed by pathology and histology, and who are judged by the doctor to be suitable for receiving the nvolimab combined with recombinant human endostatin (endostatin) in this study. * Previously received second-line standard systemic therapy (chemotherapy cycle at least ≥3 cycles), including fluorouracil or its derivatives, oxaliplatin, irinotecan and bevacizumab treatment, disease progression during or after treatment or Relapse, and have not received immune checkpoint inhibitor therapy before; Note: Patients who have received one regimen of adjuvant or neoadjuvant chemotherapy can be enrolled if they relapse \> 6 months after the end of chemotherapy; * Patients with MSS/pMMR type detected by PCR or IHC in the central laboratory; * Patients with at least one measurable lesion according to RECIST 1.1, the efficacy evaluation standard for solid tumors, that is, in CT or MRI detection, the longest diameter of a single lesion is ≥10mm, or the lymph node is pathologically enlarged, and a single lymph node CT scan has a short diameter ≥15mm; * Satisfactory main organ function，laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/L, neutrophil count（ANC） ≥1.5×109/L, platelet count（PLT） ≥80×109/L, Serum creatinine（CR）≤1.5 upper normal limitation (UNL)，total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the AST/ALT must be ≤5.0 UNL), Activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN; left ventricular ejection fraction (LVEF) ≥ 50%; thyroid stimulating hormone (TSH) within the normal range Within: if the baseline TSH exceeds the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled; * Subjects of childbearing potential must use an appropriate method of contraception during the study period and within 120 days after the end of the study, have a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating subjects
Exclusion criteria
* Suffered from other malignant tumors within 3 years before the start of treatment in this study; * The pathological indication is mucinous adenocarcinoma and other special pathological types; * Grade ≥1 unresolved toxicities (according to the most recent version of the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\]) due to any prior therapy, excluding alopecia and fatigue; neurotoxicity was Recovery to ≤ grade 1 or baseline before the group; * Subjects with any severe and/or uncontrolled disease ； * Poorly controlled diabetes (fasting blood glucose \[FBG\] \> 10 mmol/L) ； * Received major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment; or had a long-term unhealed wound or fracture； * Serious arterial/venous thrombotic event within 6 months prior to initiation of study treatment ； * Previously received drug therapy against PD-1, PD-L1 and other related immune checkpoints ； * Participating in or participating in other clinical investigators within 4 weeks prior to the start of the study ； * Allergic to the active ingredients or excipients of the study drug ； * Unsuitable for the study or other chemotherapy determined by investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR | From Baseline to disease progress, up to 24 months | Objective response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | From Baseline to primary completion date, about 2 years | Progression Free Survival |
| OS | From Baseline to primary completion date, about 2 years | Overall Survival |
| DCR | From Baseline to primary completion date, about 2 years | Disease Control Rate |
| DOR | From Baseline to primary completion date, about 2 years | Duration of Response |
| SAE | From Baseline to primary completion date, about 2 years | severity Adverse Event |
Contacts
Primary ContactEnxiao Li
Outcome results
None listed